Abstract: 4-Quinoline-carboxylic acid derivatives, such as 2-(2'-fluoro-1,1'-biphenyl-4-yl)-6-fluoro-3-methyl-4-quinoline carboxylic acid, in combination with other immunosuppressive agents are useful for the treatment and/or prevention of transplantation rejection, graft vs. host disease, autoimmune diseases, and chronic inflammatory disease.
Abstract: Processes are provided for preparing crystalline moricizine hydrochloride from moricizine using hydrochloric acid, wherein the crystalline moricizine hydrochloride so obtained is substantially free of occluded water.
Abstract: Physically and chemically stable pharmaceutical compositions useful for administering etanidazole by injection are described. These compositions are essentially aqueous solutions having a pH less than or equal to 5.5, and containing etanidazole, a buffer system, and a tonicity-adjusting agent, and they are optionally stabilized by the addition of a stabilizing agent or by autoclaving.
Type:
Grant
Filed:
June 26, 1992
Date of Patent:
March 9, 1993
Assignee:
Du Pont Merck Pharmaceutical Company
Inventors:
Surendra M. Bahal, Kenneth S. Field, Michael B. Maurin
Abstract: Peptides comprising C-terminal boronic acid derivatives of lysine, ornithine, and arginine, homoarginine and corresponding isothiouronium analogs thereof, are reversible inhibitors of trypsin-like serine proteases such as thrombin, plasma kallikrein and plasmin.
Type:
Grant
Filed:
April 6, 1988
Date of Patent:
February 16, 1993
Assignee:
Du Pont Merck Pharmaceutical Company
Inventors:
Charles A. Kettner, Ashokkumar B. Shenvi
Abstract: Ketones having formulas (1)-(3) are provided by improved methods which involve the treatment of compounds having formulas (9)-(11) with aqueous base. ##STR1## wherein R.sub.x is NO.sub.2.
Abstract: The invention relates to a method of treating cocaine abuse or addiction in a mammal which comprises administering to the mammal an effective amount of a sigma receptor antagonist lacking or having relatively weak dopamine receptor-blocking activity, to reduce the pharmacological effects of the cocaine.
Abstract: This disclosure relates to a method of treating a neurological dysfunction in a mammal using a combination of at least one neurotransmitter enhancer and at least one serotonin receptor antagonist.
Type:
Grant
Filed:
July 13, 1990
Date of Patent:
December 15, 1992
Assignee:
Du Pont Merck Pharmaceutical Company
Inventors:
Kimi F. De Noble, Victor J. De Noble, Richard A. Earl, Melvyn J. Myers, Victor J. Nickolson
Abstract: The invention relates to a method of treating drug abuse or addiction involving amphetamine or amphetamine-related drugs with pharmacological effects similar to amphetamine in a mammal which comprises administering to the mammal an effective amount, to reduce the pharmacological effects of the amphetamine or amphetamine-related drug, of certain piperidine sigma receptor antagonists.
Abstract: Biologically active analogs of human IL2, which differ from natural IL2 by the substitution of amino acid residues to form N-linked glycosylation sites in the molecule, are prepared by recombinant DNA techniques. Such analogs of IL2 are N-linked glycosylated when expressed in eukaryotic cells. Natural IL2 is not N-linked glycosylated.
Abstract: The invention relates to ultrasound contrast agents comprising porous particles of an inorganic material containing an entrapped gas or liquid and having an average particle diameter of about 0.05 to 500 microns, said inorganic material being selected from one or more of the group consisting of: monomeric or polymeric borates; monomeric or polymeric aluminas; monomeric or polymeric carbonates; monomeric or polymeric silicas; and monomeric or polymeric phosphates; and pharmaceutically acceptable organic or inorganic cationic salts thereof.
Type:
Grant
Filed:
April 30, 1991
Date of Patent:
September 15, 1992
Assignee:
Du Pont Merck Pharmaceutical Company
Inventors:
Joseph L. Glajch, Gary L. Loomis, Walter Mahler
Abstract: There is disclosed a perfusable cell culture device capable of expansion and maintenance of biological cells, including mammalian, microbial, plant and insect cells in culture. The device comprises an upper and lower polymeric film layer and a gas and liquid permeable flow divider membrane. The flow divider membrane is affixed between the upper and lower polymeric layers and to the lower polymeric layer in a manner providing channels for fluid distribution of culture medium which is perfused at a controlled rate, uniformly across the flow divider membrane and to a bed of cells dispersed on the flow divider membrane.
Type:
Grant
Filed:
July 9, 1991
Date of Patent:
August 18, 1992
Assignee:
Du Pont Merck Pharmaceutical Company
Inventors:
Gary W. Howell, Joseph D. Irr, Ara T. Nahapetian
Abstract: Dihydrobenz[c]acridine carboxylic acid derivatives are provided which are useful for the treatment and/or prevention of organ transplantation rejection, graft versus host disease, autoimmune diseases, psoriasis and chronic inflammatory diseases.
Abstract: There are provided cycloalkyl piperidine compounds which are useful in the treatment of physiological or drug-induced psychosis or dyskinesia in a mammal. These novel compounds are selective sigma receptor antagonists and have a low potential for movement disorder side effects associated with typical antipsychotic agents.
Type:
Grant
Filed:
August 20, 1990
Date of Patent:
April 28, 1992
Assignee:
Du Pont Merck Pharmaceutical Company
Inventors:
Gary A. Cain, Paul J. Gilligan, Sang W. Tam
Abstract: The pyrimidine biosynthesis inhibitors dichloroallyl lawsone, N-(phosphonoacetyl)-L-aspartic acid (PALA), pyrazofurin, and derivatives thereof, are useful as immunomodulatory and anti-inflammatory agents. Pharmaceutical formulations containing these compounds are useful for the treatment of autoimmune diseases, chronic inflammatory diseases, and of organ transplantation rejections.